Current opinion in neurological manifestations of SARS-CoV-2 infection

ENGİN A. B., ENGİN E. D., ENGİN A.

CURRENT OPINION IN TOXICOLOGY, cilt.25, ss.49-56, 2021 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.cotox.2021.03.004
  • Dergi Adı: CURRENT OPINION IN TOXICOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.49-56
  • Anahtar Kelimeler: COVID-19, Blood-brain barrier, ACE2, Thromboembolic complications, IL-6, Neuropilin-1, MITOCHONDRIAL DYSFUNCTION, BRAIN, RECEPTOR, DISEASE, ACE2, EXCITOTOXICITY, EXPRESSION, ANG-(1-7), COVID-19
  • Gazi Üniversitesi Adresli: Evet

Özet

Neurological symptoms occur in approximately one-third of hospitalized patients with coronavirus disease 2019 (COVID-19). Among these symptoms, hypoxic encephalopathy develops in one-fifth of severe cases, while ischemic strokes due to thrombotic complications are common in one-third of COVID-19 intensive care patients. Brain involvement of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is eventuated by several routes, including hematogenous spread, transsynaptic entry through infected neurons, olfactory nerve, ocular epithelium, vascular endothelium, and impaired blood- brain barrier. Besides the high angiotensin-converting enzyme-2 (ACE2) binding affinity, and FURIN preactivation, SARS-CoV-2 maintains efficient neuronal entry while evading immune surveillance by using basigin and neuropilin-1 receptors. However, the neurological manifestations and their pathogenic mechanisms are still debated in COVID-19 patients.